TFF2 and obesity due to melanocortin 4 receptor deficiency: Importantly, extrapolating these concepts from mice to humans and building clinical trials based on animal experiments could lead to developing novel TFF2-based therapies for diseases and conditions, such as inflammation, and, most importantly, a potential control for lipid intake (appetite control) towards a better obesity management strategy, which requires urgent solutions due obesity’s epidemiological profile and its impacts on health and the economy [43,44,45,46].